Richard Clegg - May 12, 2025 Mewburn Ellis relocates London office to 8 Bishopsgate, furthering commitment to sustainability and growth We are delighted to announce the relocation of our London office to the landmark eco-friendly tower ...
Richard Clegg - May 1, 2025 Top patent litigator Camilla Balleny to head Mewburn Ellis patent litigation team We are delighted to announce that life sciences and healthcare specialist litigator Camilla Balleny ...
Richard Clegg - July 31, 2024 New EU sanctions against Russia In late June the EU extended their package of sanctions in view of Russia’s actions in Ukraine by ...
Richard Clegg - October 23, 2023 Andy King appointed as Head of Trade Marks and joins the firm’s Management Board We're pleased to announce that Partner Andy King will be the new Head of the Trade Mark Practice ...
Eliot Ward - October 4, 2023 UPC at four months old - a review The UPC is now four months old and the Court of First Instance is already quite busy. As of 4 ...
Maria Hall - September 19, 2023 Mewburn Ellis praised for achievements in sustainability EcoVadis ratings highlight environmental policies and sustainable procurement practices alongside ...
Jacqueline Murphy - March 7, 2023 Come and join us for a ‘Celebration of all things Singapore’ We are excited to be in Singapore for INTA 2023 and very much hope that you can join us at our ...
Richard Clegg - January 18, 2023 Opting out from the UPC – when to opt-out a pending European patent application From 1 March 2023, when the Unified Patent Court (UPC) sunrise period starts, it will become ...
Maria Hall - October 14, 2022 Robert Watson elected President of FICPI’s Study and Work Committee Partner Robert Watson was elected President of FICPI’s Study and Work Committee (Commission d'Etude ...
Jacqueline Murphy - September 30, 2021 Mewburn Ellis: top tier firm Legal 500 2022 Mewburn Ellis is proud to be ranked top tier for our patent and trade mark practices in the 2022 ...
Richard Clegg - August 6, 2021 Mewburn Ellis board signs IP Inclusive Leaders’ Pledge Mewburn Ellis’ nine board members are proud to be amongst dozens of leadership signatories to the ...
Richard Clegg - November 19, 2020 Diversity & inclusion is high on our agenda Diversity & inclusion is high on the agenda for Mewburn Ellis, it’s part of our business plan ...
Richard Clegg - May 14, 2020 Singapore's biotech breakthrough From the far east to the east coast of America, the world is taking note of a new energy surging ...
Richard Clegg - March 20, 2020 Changes to our correspondence address In response to the current situation in London due to Coronavirus (COVID-19) we are redirecting all ...
Richard Clegg - February 12, 2020 Oppositions & Appeals: we opened the door for different types of data to support a medical use Case 4 - T 801/06 (EPO Board of Appeal, 4 March 2009)
Richard Clegg - November 15, 2019 Meet the team: Richard Clegg, Partner, European Patent Attorney, Patent Attorney Litigator As part of our 'meet the team' series, we talk to Richard Clegg about his journey to becoming a ...
Richard Clegg - August 13, 2019 Challenges Post Selex Twenty-five years ago Tuerk and Gold reported the Selex method. Being the first European patent ...
Richard Clegg - December 10, 2018 Clovis Oncology success in European Opposition Proceedings related to Rubraca® Clovis Oncology has announced that the European Patent Office (EPO) last week upheld claims of ...
Richard Clegg - October 31, 2018 Morphosis: creating and nurturing biotech start-ups in Singapore We understand that early-stage biotech companies do not have it easy. It is a long road from ...
